GYRE vs MDGL
GYRE: A China-based biopharmaceutical company generating revenue from approved antifibrotic treatments while advancing late-stage candidates for liver and other organ fibrosis in the U.S. market. MDGL: Madrigal Pharmaceuticals is a biopharmaceutical company commercializing Rezdiffra, the first and only FDA-approved therapy for adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis.
Side-by-side fundamentals
| Metric | GYRE | MDGL | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $6.13 | $551.25 | |
| Market cap as of 2026-08-03 | $641M | $12.7B | |
| P/E as of 2026-08-03 | 127.52 | n/a | |
| PEG as of 2026-08-03 | n/a | -134.35 | |
| Net margin as of 2026-08-03 | -5.4% | -27.3% | GYRE higher |
| Gross margin as of 2026-08-03 | +95.1% | +93.1% | GYRE higher |
| Operating margin as of 2026-08-03 | -0.1% | -27.9% | GYRE higher |
| ROE as of 2026-08-03 | -6.3% | -50.1% | GYRE higher |
| ROA as of 2026-08-03 | -4.0% | -25.4% | GYRE higher |
| Debt / equity as of 2026-08-03 | 0.00 | 0.63 | GYRE lower |
| Revenue growth (YoY) as of 2026-08-03 | +16.3% | +256.8% | MDGL higher |
| Revenue CAGR (3y) SEC XBRL | +4.5% | n/a | |
| Dividend streak (yrs) SEC XBRL | 1 | n/a | |
| Beta as of 2026-08-03 | 2.36 | -1.05 | |
| 1-year return as of 2026-07-27 close | -19.8% | +84.7% | MDGL higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.